APA (7th ed.) Citation

Z, A., SI, H., AA, J., A, S., E, A., M, B., . . . AA, R. (2026). Rivaroxaban versus Low Molecular Weight Heparin for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 32, 10760296261459711. https://doi.org/10.1177/10760296261459711

Chicago Style (17th ed.) Citation

Z, Adnan, et al. "Rivaroxaban Versus Low Molecular Weight Heparin for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis." Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 32 (2026): 10760296261459711. https://doi.org/10.1177/10760296261459711.

MLA (9th ed.) Citation

Z, Adnan, et al. "Rivaroxaban Versus Low Molecular Weight Heparin for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis." Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, vol. 32, 2026, p. 10760296261459711, https://doi.org/10.1177/10760296261459711.